Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5432748 | 0.91 | SIGMAR1 (0.40) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL6936162 | 0.86 | IDO1 (0.49) | TAAR1IDO1AGXTMAOBGABRG2 | |
| SCHEMBL29910773 | 0.86 | IDO1 (0.49) | TAAR1IDO1AGXTMAOBGABRG2 | |
| SCHEMBL2466725 | 0.84 | PPARA (0.39) | TAAR1SIGMAR1HTR2CSLC6A4HTR2B | |
| SCHEMBL4331861 | 0.80 | MAOA (0.42) | MAOB | |
| SCHEMBL15987305 | 0.80 | MRGPRX4 (0.44) | — | |
| SCHEMBL333905 | 0.80 | TAAR1 (0.46) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL6589309 | 0.80 | MAOB (0.47) | MAOB | |
| SCHEMBL20954611 | 0.78 | ALDH1A1 (0.48) | MAOB | |
| SCHEMBL29371114 | 0.78 | ALDH1A1 (0.48) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772490-B1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2772490-B1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2772490-A1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2772490-A1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | SLC34A2, SLC10A2, ALPI | TAAR1 2103/4885IDO1 2918/4885AGXT 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.